ecp for immune-related adverse events after checkpoint inhibitor treatment

Conditions: Immune Related Adverse Events; Colitis; Hepatitis; Dermatitis

Summary: preliminary data demonstrate that iraes induced by immune checkpoint blockade can be successfully treated with ecp (apostolova et al. nejm 2020). therefore this retrospective analysis is launched to validate the finding made with the individual patient in a larger patient cohort. the analysis will include the evaluation of safety of ecp treatment in patients with iraes and collect data on the efficacy of ecp as a treatment for immune-related adverse events and its effect on tumor progression.

immune checkpoint inhibitors (ici) have improved the long-term survival of patients with metastatic tumors. however, approximately 50% of the patients treated with ici develop serious immune-related adverse events (irae). a recent study reported that grade 3 or higher irae occurred in 49 of 124 patients (39.5%) who received nivolumab/ipilimumab and in 41 of 123 patients (33.3%) who received nivolumab alone. other studies report an overall frequency of grade 3-5 irae in 24% - 59% of patients treated with nivolumab 1 mg/kg body weight and ipilimumab 3 mg/kg body weight. an incidence of 33.3% was reported when patients were treated with nivolumab 3 mg/kg body weight and ipilimumab 1 mg/kg body weight. the most common events reported during combined ici treatment are diarrhea, rash, pruritus, hepatitis, hypothyroidism, neurological disease and pneumonitis. these numbers show that irae are a particularly frequent complication of ici and limit their use. this retrospective analysis is launched to validate the finding made with the individual patient in a larger patient cohort. the analysis will include the evaluation of safety of ecp treatment in patients with iraes and collect data on the efficacy of ecp as a treatment for immune-related adverse events and its effect on tumor progression.

Eligibility criteria:
inclusion criteria: 1. male and female patients aged ≥18 years 2. written informed consent: * subjects must have signed and dated an irb/iec approved written informed consent form in accordance with regulatory and institutional guidelines. * subjects must be able to understand and willing to comply with scheduled visits, treatment schedule, laboratory tests and mandatory collection of blood, and other requirements of the study. * subject re-enrollment: this trial permits the re-enrollment of a subject that has discontinued the study as a screening failure. if re-enrolled, the subject must be re-consented. 3. target population * patients who have received treatment with an anti-pd-1, anti-pd-l1 or an anti-ctla-4 antibody or any combination of these for any type of malignancy in the last 24 months before screening. * patients should have clinical and/or histological evidence of immune-related adverse events as follows: * colitis diarrhea with increase of ≥4 stools over baseline no improvement after 72h treatment with at least 1 mg/kg bw/day prednisolone equivalent * hepatitis alanine aminotransferase and/or aspartate aminotransferase ≥3x uln if baseline was normal; or ≥3x baseline if baseline was abnormal no improvement after 72h treatment with at least 1 mg/kg bw/day prednisolone equivalent * pneumonitis radiographic changes and new symptoms such as cough, dyspnea or chest pain no improvement after 72h treatment with 1 mg/kg bw/day prednisolone equivalent dermatitis skin erythema, maculopapular or pustulopapular rash covering ≥30% of the body surface area no improvement after 72h treatment with at least 1 mg/kg bw/day prednisolone equivalent 4. maximum of one additional (second line) therapy after steroid treatment before ecp starts (e.g. infliximab for colitis) 5. women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 iu/l or equivalent units of hcg) within 1 week prior to the start of study drug. 6. women must not be breastfeeding. 7. ecog performance status 0, 1, or 2 exclusion criteria: 1. active treatment in a clinical study of any investigational agent within 14 days prior day 0 or within 5 half-lives of the study treatment, whichever is greater. 2. positive result for hiv. 3. prior allogeneic bone marrow transplantation or prior solid organ transplantation. 4. mechanical ventilation or patients who have resting o2 saturation \<90% by pulse-oximetry. 5. patients who require vasopressors, and/or have nyha class iii or iv heart failure. 6. uncontrolled hypertension or ventricular arrhythmias. 7. previous or concurrent malignancies within the last 3 years of enrollment other than the disease for which checkpoint-inhibitor blockade was applied. exceptions are adequately treated basal or squamous cell skin cancer, or any other cancer from which the subject has been disease-free for more than 3 years. 8. any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the subject; or interfere with interpretation of study data 9. known allergies, hypersensitivity, or intolerance of methoxypsoralen, excipients, or similar compounds, heparin or similar compounds 10. aphakia 11. female patients of child-bearing potential who are not willing to use highly effective methods of contraception during the trial and at least 5 months after the ecp procedure (see also 10.9) 12. inability to tolerate extracorporeal volume loss 13. previous splenectomy 14. pregnancy and lactation

Keywords: extracorporeal photoperesis immune modulation immune checkpoint inhibitor